Page 8 - UHN-RR2021

RESEARCH COMMERCIALIZATION

Moving Research

Forward

Working with industry to unlock A Healthier World

#1

Canadian Research
Commercialization
Institution $1.1B
Recent Financing
Raised for Our
Start-Ups
100%
of Our Spin-Offs $68M
Have Operations Licencing Revenue
in Toronto Reinvested over the
Past Three Years

Today’s researchers play a key role in turning their TRANSLATION
findings into treatments and technologies that 2020 HIGHLIGHTS
benefit patients. Whether it is through launching
a start-up, drug discovery activities or designing Oncology start-up POINT SURGICAL
medical devices, the private sector works together INC. launches to develop a way to
with researchers to bring health care solutions to instantly and accurately diagnose cancer
patients. This is why we commercialize. types using laser vaporization and mass
spectrometry

Thanks to our world-class researchers and Cancer start-up TCRYPTION Inc.
clinicians, UHN is now Canada’s leading launches (see next page)
institution in research commercialization and the
eighth top hospital in North America in research POINT BIOPHARMA and UHN’s
translation [AUTM Licensing Activity Survey]. CANPROBE sign an exclusive licensing
agreement to develop the therapeutic
compound Lu-DOTATATE, advancing
Our commercialization achievements include 14 options for patients with difficult-to-treat
funded spin-offs since 2014, which are creating jobs neuroendocrine cancer
in Toronto, and $68M raised in licensing revenue in
the last three years—funds that are being reinvested SONA GROUP and VEE TECH
to further propel innovation at UHN. enter a collaboration with UHN to
develop smart fabric-based wearables to
improve the quality of life of individuals
Read on to see our progress over the last fiscal experiencing chronic illness, aging and
year, and to learn how our research discoveries disabilities
are improving the health of Canadians and people
around the world. Next-generation cancer diagnostics start-
up ADELA launches (see next page)

6 2021